Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1 Advancing ASO therapy for neurological disorders.

Published byEzra Stone Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1 Advancing ASO therapy for neurological disorders."— Presentation transcript:

1 Fig. 1 Advancing ASO therapy for neurological disorders.
Advancing ASO therapy for neurological disorders. Future advances in ASO therapy for neuromuscular and neurodegenerative disorders will depend on both technical advances (left) and improved screening and biomarker strategies for identifying patients during the earliest stages of disease (right). Development of next-generation ASO compounds will arise from advances in oligonucleotide chemistry, including stereoselective synthesis, coupled with technologies that solve the challenges of intracellular ASO delivery and delivery across the blood-brain barrier. Last, the ability to assess the true clinical effectiveness of ASO therapies will be driven not only by presymptomatic genetic screening of neonates or at-risk family members but also by development of more robust clinical trial outcome measures, including development of digital technologies and devices that will have implications for reductions in clinical trial size, duration, and ultimately cost. Kevin Talbot and Matthew J. A. Wood Sci Transl Med 2019;11:eaay2069 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

Download ppt "Fig. 1 Advancing ASO therapy for neurological disorders."

Similar presentations

Demonstrations I, II, and III.

Demonstrations I, II, and III.
Three different types of transfer functions with a codomain of [0,1].

Three different types of transfer functions with a codomain of [0,1].
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 1 Movement percepts for all participants.

Fig. 1 Movement percepts for all participants.
Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.
Fig. 2 Transport properties of a BP transistor at low temperature.

Fig. 2 Transport properties of a BP transistor at low temperature.
Fig. 2 Optimized syntheses and crystallographic characterization of borylene dinitrogen compounds. Optimized syntheses and crystallographic characterization.

Fig. 2 Optimized syntheses and crystallographic characterization of borylene dinitrogen compounds. Optimized syntheses and crystallographic characterization.
Fig. 1 ZIKV RNA in blood and tissues.

Fig. 1 ZIKV RNA in blood and tissues.
Fig. 2 Global production, use, and fate of polymer resins, synthetic fibers, and additives (1950 to 2015; in million metric tons). Global production, use,

Fig. 2 Global production, use, and fate of polymer resins, synthetic fibers, and additives (1950 to 2015; in million metric tons). Global production, use,
Fig. 4 Mutations and reduced expression of human KDM6A predict poor prognosis of female patients with BCa. Mutations and reduced expression of human KDM6A.

Fig. 4 Mutations and reduced expression of human KDM6A predict poor prognosis of female patients with BCa. Mutations and reduced expression of human KDM6A.
Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.
Fig. 1 Map of water stress and shale plays.

Fig. 1 Map of water stress and shale plays.
In vivo release of doxycycline hyclate from the GRS in a swine model

In vivo release of doxycycline hyclate from the GRS in a swine model
Brain-computer interfaces.

Brain-computer interfaces.
Fig. 2 Paralog-selective inhibitors of GSK3α and GSK3β were designed and characterized. Paralog-selective inhibitors of GSK3α and GSK3β were designed and.

Fig. 2 Paralog-selective inhibitors of GSK3α and GSK3β were designed and characterized. Paralog-selective inhibitors of GSK3α and GSK3β were designed and.
Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 5. In vivo characterization of adipogenesis by CT.
Fig. 3 Rotation experiment, setup.

Fig. 3 Rotation experiment, setup.

Similar presentations

Ads by Google